This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Dks Co. Ltd., Other. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Toshiyuki Morisawa: Innovator in Subcutaneous Expansion Agents
Introduction
Toshiyuki Morisawa is a notable inventor based in Nishinomiya, Japan. He has made significant contributions to the field of medical technology, particularly in the development of subcutaneous or submucosal expansion agents. His innovative approach aims to enhance the effectiveness and longevity of these agents in medical applications.
Latest Patents
Morisawa holds a patent for a subcutaneous or submucosal expansion agent. The objective of this invention is to provide an agent that not only exhibits superior expansion properties compared to conventional agents but also maintains the expanded state for an extended period. This agent is designed to be injected into subcutaneous or submucosal spaces, comprising cellulose fibers that contain anionically modified cellulose and water. This formulation ensures sufficient administration properties, making it a valuable advancement in medical treatments.
Career Highlights
Throughout his career, Morisawa has worked with various companies, including DKS Co. Ltd. His experience in the industry has allowed him to refine his inventions and contribute to advancements in medical technology. His work has been recognized for its potential impact on patient care and treatment options.
Collaborations
Morisawa has collaborated with notable individuals in his field, including Takayuki Hayashi and Yosuke Goi. These collaborations have fostered innovation and have been instrumental in the development of his patented technologies.
Conclusion
Toshiyuki Morisawa's contributions to the field of subcutaneous expansion agents highlight his innovative spirit and dedication to improving medical technology. His patent represents a significant advancement that could enhance patient outcomes in various medical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile